Short Interest in Mural Oncology plc (NASDAQ:MURA) Declines By 15.7%

Mural Oncology plc (NASDAQ:MURA) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 392,800 shares, a decline of 15.7% from the September 30th total of 465,800 shares. Based on an average daily volume of 94,200 shares, the short-interest ratio is currently 4.2 days. Currently, 2.5% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MURA. HC Wainwright started coverage on shares of Mural Oncology in a report on Thursday, October 17th. They set a “buy” rating and a $18.00 target price on the stock. Raymond James started coverage on Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target on the stock.

Institutional Trading of Mural Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BBR Partners LLC acquired a new position in shares of Mural Oncology in the second quarter worth about $31,000. Rhumbline Advisers acquired a new stake in Mural Oncology in the second quarter valued at approximately $34,000. Canada Pension Plan Investment Board purchased a new stake in shares of Mural Oncology in the second quarter valued at approximately $70,000. Dimensional Fund Advisors LP acquired a new position in shares of Mural Oncology during the 2nd quarter worth approximately $71,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $84,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Mural Oncology Trading Down 0.8 %

NASDAQ MURA traded down $0.03 on Wednesday, hitting $3.56. 45,489 shares of the company’s stock traded hands, compared to its average volume of 184,902. The firm’s 50-day moving average price is $3.33 and its two-hundred day moving average price is $3.40. The firm has a market capitalization of $60.66 million and a PE ratio of -0.34. Mural Oncology has a 1-year low of $2.88 and a 1-year high of $17.00.

Mural Oncology (NASDAQ:MURA) last posted its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. On average, research analysts anticipate that Mural Oncology will post -7.59 earnings per share for the current fiscal year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.